Evoxac Daiichi Pharmaceutical Co (Health/Medications)
evoxac.com

Description: Official pharmaceutical site with education and treatment information for patients and health professionals. EVOXAC (cevimeline HCI) 30 mg capsules, introduced in 2000, is a product marketed and distributed in the United States by Daiichi Pharmaceutical Corporation. This product is FDA approved for the treatment of dry mouth symptoms in patients with Sjgrens (SHOWgrins) syndrome

Specializes in: daiichi pharmaceutical corporation sjgrens syndrome cevimeline hcl evoxac dry mouth tongue throat eyes nose exocrine glands

Website owner:

unknown